CDXC / ChromaDex Corporation - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

NIAGEN BIOSCIENCE, INC. Amended and Restated Non-Employee Director Compensation Policy Adopted: November 8, 2016 Amended and Restated: November 16, 2016 Amended and Restated: April 6, 2017 Amended and Restated: June 22, 2018 Amended: March 3, 2025 Am

Exhibit 10.1 NIAGEN BIOSCIENCE, INC. Amended and Restated Non-Employee Director Compensation Policy Adopted: November 8, 2016 Amended and Restated: November 16, 2016 Amended and Restated: April 6, 2017 Amended and Restated: June 22, 2018 Amended: March 3, 2025 Amended and Restated: November 4, 2025 Effective Date: July 3, 2016 Each member of the Board of Directors (the “Board”) who is a member as

Niagen Bioscience, Inc. Earnings Presentation First Quarter 2026 Nasdaq: NAGE | May 6, 2026 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” w

ex992earningspresentatio Niagen Bioscience, Inc. Earnings Presentation First Quarter 2026 Nasdaq: NAGE | May 6, 2026 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 NIAGEN BIOSCIENCE, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million LOS ANGELES, CA - May 6, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 Commission File Number: 001-3775

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 Commission File Number: 001-37752 NIAGEN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 NIAGEN BIOSCIENCE, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 NIAGEN BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Exhibit 99.1 Niagen Bioscience Increases Share Repurchase Program to $20 Million LOS ANGELES – March 19, 2026 – Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company’s previously disclosed share repurchase program (th

INDEMNITY AGREEMENT

EXHIBIT 10.14 INDEMNITY AGREEMENT This Indemnity Agreement (this “Agreement”) dated as of , 20, is made by and between Niagen Bioscience, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). Recitals A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s Bylaws, as amended (the “Bylaws”),

NIAGEN BIOSCIENCE, INC. Dodd-Frank Clawback Policy

EXHIBIT 97.1 NIAGEN BIOSCIENCE, INC. Dodd-Frank Clawback Policy The Board of Directors (the “Board”) of Niagen Bioscience, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Dodd-Frank Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined

8TH MODIFICATION TO BUSINESS FINANCING AGREEMENT

EXHIBIT 10.40 8TH MODIFICATION TO BUSINESS FINANCING AGREEMENT This 8th Modification to Business Financing Agreement (this “Amendment”) is entered into as of November 12, 2025, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), NIAGEN BIOSCIENCE, INC., a Delaware corporation (formerly known as CHROMADEX CORPORATION, a Delaware corporation), CHROMADEX, INC., a California corpora

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps ye

EXHIBIT 99.1 Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103% year-over-year to $17.4 million in 2025 Adjusted EBITDA increased 139% year-over-

FIRST AMENDMENT TO NIAGEN BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN

EXHIBIT 10.8 FIRST AMENDMENT TO NIAGEN BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN WHEREAS, Niagen Bioscience, Inc. (the “Company”) maintains the Niagen Bioscience, Inc. Employee Stock Purchase Plan (as amended, the “Plan”); WHEREAS, pursuant to Section 20 of the Plan, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of the Company may at any time amend the Pl

Niagen Bioscience, Inc. Earnings Presentation Fourth Quarter and Full Year 2025 Nasdaq: NAGE | March 4, 2026 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-look

ex992-nageearningspresen Niagen Bioscience, Inc. Earnings Presentation Fourth Quarter and Full Year 2025 Nasdaq: NAGE | March 4, 2026 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securitie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 NIAGEN BIOSCIENCE, INC.

Policy INSIDER TRADING COMPLIANCE

EXHIBIT 19.1 NIAGEN BIOSCIENCE, INC. Date Issued: 7/23/2025 Page #: 1 of 7 Policy INSIDER TRADING COMPLIANCE Approved By: Board of Directors Department: Legal Applies To: Worldwide Operations Statement of Purpose Niagen Bioscience, Inc. (the “Company”) has adopted this Insider Trading Policy (the “Policy”) in order to take an active role in the prevention of insider trading violations by officers,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 NIAGEN BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F

(As of December 31, 2025)

EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2025) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. Niagen Bioscience, Inc. California ChromaDex International, Inc. Niagen Bioscience, Inc. Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands NAD Pharmaceuticals Corp. ChromaDex, Inc. Nevad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 NIAGEN BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissi

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities

Exhibit 99.1 Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities LOS ANGELES – Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the

REST OF PAGE HAS BEEN LEFT INTENTIONALLY BLANK

EXHIBIT 10.1 Certain information in this document (indicated by [***]) has been excluded pursuant to Regulation S-K Item 601(b)(10). Such information is not material and is treated by the Registrant as private or confidential. ASSIGNMENT THIS ASSIGNMENT is made December 16, 2025 BETWEEN: (1) QUEEN’S UNIVERSITY BELFAST, having its principal offices at University Road, Belfast BT7 1NN (the "Assignor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 NIAGEN BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissi

Niagen Bioscience Acquires Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in t

Exhibit 99.1 Niagen Bioscience Acquires Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industry LOS ANGELES – December 22, 2025 – Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide ade

Niagen Bioscience Announces $10 Million Share Repurchase Program

Exhibit 99.1 Niagen Bioscience Announces $10 Million Share Repurchase Program LOS ANGELES – November 6, 2025 – Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 NIAGEN BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio

Niagen Bioscience, Inc. Earnings Presentation Third Quarter 2025 Nasdaq: NAGE | November 4, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “fo

ex992earningspresentatio Niagen Bioscience, Inc. Earnings Presentation Third Quarter 2025 Nasdaq: NAGE | November 4, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook Net sales increased 33% to $34.0 million Gross margin increased 100 bps to 64.5% Net income of $4.6 million, up $2.7 million from the prior

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook Net sales increased 33% to $34.0 million Gross margin increased 100 bps to 64.5% Net income of $4.6 million, up $2.7 million from the prior year Adjusted EBITDA increased by 120% to $6.4 million Full year 2025 net sales outlook of 25% to 30% year-over-year growth LOS ANGELES, CA - Novembe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Commission File Number: 001-37752 NIAGEN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 NIAGEN BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

EXHIBIT 99.1 Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth LOS ANGELES-October 6, 2025- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year 2025 net sales outlook to 25% to 30% year-over-year growth from

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2025 NIAGEN BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

CALCULATION OF FILING FEE TABLES Niagen Bioscience, Inc. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Niagen Bioscience, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock,

As filed with the Securities and Exchange Commission on August 8, 2025

As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.

As filed with the Securities and Exchange Commission on August 8, 2025

As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.

CALCULATION OF FILING FEE TABLES Niagen Bioscience, Inc. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Niagen Bioscience, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 NIAGEN BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth LOS ANGELES, CA -

Niagen Bioscience, Inc. Earnings Presentation Second Quarter 2025 Nasdaq: NAGE | August 6, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “for

ex992earningspresentatio Niagen Bioscience, Inc. Earnings Presentation Second Quarter 2025 Nasdaq: NAGE | August 6, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission File Number: 001-37752

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission File Number: 001-37752 NIAGEN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 NIAGEN BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F

Sales Agreement, dated July 25, 2025, by and between ChromaDex, Inc. and W. R. Grace & Co.-Conn. *

Exhibit 10.1 Certain information in this document (indicated by [***]) has been excluded pursuant to Regulation S-K Item 601(b)(10). Such information is not material and is treated by the Registrant as private or confidential. SALES AGREEMENT THIS SALES AGREEMENT (this “Agreement”) dated as of the 1st day of April, 2025 (the “Effective Date”), by and between W. R. GRACE & CO.-CONN., a Connecticut

Niagen Bioscience, Inc. Employee Stock Purchase Plan

Exhibit 10.2 NIAGEN BIOSCIENCE, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Niagen Bioscience, Inc. Employee Stock Purchase Plan (the “Plan”) is to encourage and enable Eligible Employees of Niagen Bioscience, Inc. (the “Company”) and certain Designated Subsidiaries to acquire proprietary interests in the Company through the ownership of the Company’s Common Stock purchased th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 NIAGEN BIOSCIENCE,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F

Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended

Exhibit 10.1 Niagen Bioscience, Inc. AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders June 22, 2018 Amended by the Board of Directors: April 16, 2020 Approved by the Stockholders June 19, 20

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES, CA - May 7, 2025 - Niagen Bioscience, Inc. (NASDAQ:NAGE)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number: 001-3775

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number: 001-37752 NIAGEN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or

Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.8 NIAGEN BIOSCIENCE, INC. Amended and Restated Non-Employee Director Compensation Policy Adopted: November 8, 2016 Amended and Restated: November 16, 2016 Amended and Restated: April 6, 2017 Amended and Restated: June 22, 2018 Amended: March 3, 2025 Effective Date: July 3, 2016 Each member of the Board of Directors (the “Board”) who is a member as of November 8, 2016 or thereafter and w

Form of Stock Option Agreement under Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended

Exhibit 10.6 Niagen Bioscience, Inc. 2017 Equity Incentive Plan Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) Pursuant to the accompanying Option Grant Notice (the “Grant Notice”) and this Option Agreement (the “Agreement”), Niagen Bioscience, Inc. (the “Company”) has granted you an Option under the Niagen Bioscience, Inc. 2017 Equity Incentive Plan (the “Plan”) to purchas

Form of Stock Certificate representing shares of the Registrant’s Common Stock

formofstockcertificateni THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.

Seventh Modification to Business Financing Agreement dated March 24, 2025 by and among Western Alliance Bank, Niagen Bioscience, Inc., ChromaDex Inc. and ChromaDex Analytics, Inc.

Exhibit 10.4 SEVENTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Seventh Modification to Business Financing Agreement (this “Amendment”) is entered into as of March 24, 2025, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), NIAGEN BIOSCIENCE, INC., a Delaware corporation (formerly known as CHROMADEX CORPORATION, a Delaware corporation), CHROMADEX, INC., a California cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 NIAGEN BIOSCIENCE, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Niagen Bioscience, Inc. Earnings Presentation First Quarter 2025 Nasdaq: NAGE | May 7, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward

ex992earningspresentatio Niagen Bioscience, Inc. Earnings Presentation First Quarter 2025 Nasdaq: NAGE | May 7, 2025 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Secu

Second Amendment to Lease Agreement, dated March 11, 2025, by and between ChromaDex Analytics, Inc. and 62 1625-1751 S. Fordham LLC and 64 1625-1751 S. Fordham LLC

Exhibit 10.3 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Second Amendment”) is made as of March 11, 2025, by and between 62 1625-1751 S. FORDHAM LLC, a Colorado limited liability company and 64 1625-1751 S. FORDHAM LLC, a Colorado limited liability company (as tenantsin-common, collectively the “Landlord”) and CHROMADEX ANALYTICS, INC., a Nevada corporation (hereinafter referre

Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended

Exhibit 10.5 Niagen Bioscience, Inc. AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders June 22, 2018 Amended by the Board of Directors: April 16, 2020 Approved by the Stockholders June 19, 20

Amended and Restated Incentive Compensation Recoupment Policy

Exhibit 10.9 NIAGEN BIOSCIENCE, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of Niagen Bioscience, Inc. (the “Company”) has determined that it is in the best interests of the Company to adopt this Amended and Restated Incentive Compensation Recoupment Policy (the “A&R Policy”), which amends and restates the Company’s Incenti

Form of Restricted Stock Purchase Agreement under the Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended

Exhibit 10.7 Niagen Bioscience, Inc. 2017 Equity Incentive Plan Restricted Stock Unit Award Agreement Pursuant to the accompanying Restricted Stock Unit Award Grant Notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”), Niagen Bioscience, Inc. (the “Company”) has granted you a Restricted Stock Unit Award (the “Award”) under the Niagen Bioscience, Inc. 2017 Eq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 NIAGEN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation

niagenbioscienceinc-deam Delaware The First State Page 1 4564086 8100 Authentication: 203188858 SR# 20251087401 Date: 03-17-25 You may verify this certificate online at corp.

Amended and Restated Bylaws of Niagen Bioscience, Inc.

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF NIAGEN BIOSCIENCE, INC. (hereinafter called the “Corporation”) ARTICLE I. OFFICES Section 1. Registered Office. The registered office of the Corporation in the State of Delaware shall be in the Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware, 19801 and the name of the registered agent of the Corporat

ChromaDex Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science The rebrand celebrates the company’s clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most we

Exhibit 99.1 ChromaDex Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science The rebrand celebrates the company’s clinically proven flagship patented nicotinamide riboside (NR) ingredient, Niagen, the most well-researched, efficient, high-quality, and legal NAD+ booster available [Caption: Niagen Bioscience’s state-of-the-art research and deve

by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex Inc. and ChromaDex Analytics, Inc.

EXHIBIT 10.38 SIXTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Sixth Modification to Business Financing Agreement (this “Amendment”) is entered into as of November 18, 2024, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, and CHROMADEX ANALYTICS, INC., a Nevada corporation (indiv

Insider Trading Policy

EXHIBIT 19.1 CHROMADEX Date Issued: 3/4/2025 Page #: 1 of 7 Policy INSIDER TRADING COMPLIANCE Approved By: Board of Directors Department: Legal Applies To: Worldwide Operations Statement of Purpose ChromaDex Corporation (the “Company”) has adopted this Insider Trading Policy (the “Policy”) in order to take an active role in the prevention of insider trading violations by officers, directors, emplo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

EXHIBIT 99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior

ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025 2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking stateme

ex992-cdxcearningspresen ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025 2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Offer Letter, dated June 27, 2024, by and between Carlos Lopez and ChromaDex, Inc.

EXHIBIT 10.58 June 27, 2024 CONFIDENTIAL Carlos Lopez ** RE: Offer of Employment as Senior Vice President, General Counsel for ChromaDex, Inc. Dear Carlos Lopez, We are pleased to extend you an offer of full-time employment for the position of Senior Vice President, General Counsel. ChromaDex, Inc. (“ChromaDex”), a subsidiary of ChromaDex, Corp., whose corporate headquarters is located at 10900 Wi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 CHROMADEX CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Subsidiaries of ChromaDex Corporation

EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2024) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlık Ürünleri Anonim Şirketia ChromaDex

Amendment to Amended and Restated Executive Employment Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant

EXHIBIT 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is dated as of February 25, 2025 (the “Amendment Effective Date”), by and among ChromaDex Corporation., a Delaware corporation (the “Company”), and Robert Fried, the undersigned individual (“Executive” and, together with the Company, the “Parties”), is intended to modify the Amended and Restate

Performance Stock Unit Award Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant

Exhibit 10.2 ChromaDex Corporation Performance Stock Unit Award Grant Notice (2017 Equity Incentive Plan) ChromaDex Corporation (the “Company”), pursuant to its 2017 Equity Incentive Plan (as amended from time-to-time, the “Plan”), hereby awards to Participant a performance stock unit award that grants Participant the right to receive the number of shares of Common Stock specified below (“Performa

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Amendment No. 1, dated November 20, 2024, to the At Market Issuance Sale Agreement, dated June 12, 2020

CHROMADEX CORPORATION AMENDMENT NO. 1 TO AT MARKET ISSUANCE SALES AGREEMENT November 20, 2024 Raymond James & Associates, Inc. 277 Park Avenue, Suite 410 New York, New York 10172 Attention: Stuart Barich and Tom Donegan Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, California 92660 Attention: Paul Zaffaroni and Jonathan Alyn Ladies and Gentlemen: This Amendment No. 1

ChromaDex Corporation $47,800,000 Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-272828 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated July 5, 2023 (To Prospectus dated July 5, 2023) ChromaDex Corporation $47,800,000 Common Stock This supplement (this “Supplement”) supplements the prospectus supplement, dated July 5, 2023 (the “Prospectus Supplement”), relating to the sale of shares of our common stock, $0.001 par val

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

ChromaDex Corporation Reports Third Quarter 2024 Financial Results Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and Adjusted EBITDA of $1.9 million and $2.9 million, respectively

ChromaDex Corporation Reports Third Quarter 2024 Financial Results Total net sales of $25.

Tenth Amendment to Manufacturing and Supply Agreement, dated as of January 1, 2025, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn.**

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TENTH AMENDMENT Manufacturing and Supply Agreement between W. R. Grace & Co.-Conn. and ChromaDex, Inc. This Tenth Amendment (the “Tenth Amendment") to that certain Manufacturing and Supply Ag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

ChromaDex Earnings Presentation Third Quarter 2024 Rob Fried Chief Executive Officer Ozan Pamir Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | October 31, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This

ChromaDex Earnings Presentation Third Quarter 2024 Rob Fried Chief Executive Officer Ozan Pamir Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | October 31, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

EXHIBIT 99.1 ChromaDex Appoints Ozan Pamir as Chief Financial Officer LOS ANGELES – Friday, September 20, 2024 – ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accountin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio

Offer Letter, dated September 10, 2024, by and between Ozan Pamir and ChromaDex, Inc.

10900 Wilshire Blvd, Suite 600 | Westwood, CA 90024 USA | T: +1 310-388-6706 | www.

CDXC / ChromaDex Corporation / Prime Tech Global Ltd - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 9)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0,001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Li Ka Shing Attention: Pau

Joint Filing Agreement

EX-99.1 2 d863039dex991.htm EX-99.1 CUSIP No. 171077407 SC 13D/A Page 23 of 24 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule

Joint Filing Agreement

EX-99.1 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have

SECURITIES PURCHASE AGREEMENT

EX-99.11 Exhibit 99.11 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made on 20 August, 2024 BY AND AMONG: (1) Prime Tech Global Limited, a British Virgin Islands company (“Prime Tech”); (2) Alpha Mount International Limited, a British Virgin Islands company (“Alpha Mount” and together with Prime Tech, the “Sellers”); (3) Brilliant Dynasty Limited, a Britis

SECURITIES PURCHASE AGREEMENT

EX-99.16 3 d863039dex9916.htm EX-99.16 Exhibit 99.16 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made on 20 August, 2024 BY AND AMONG: (1) Prime Tech Global Limited, a British Virgin Islands company (“Prime Tech”); (2) Alpha Mount International Limited, a British Virgin Islands company (“Alpha Mount” and together with Prime Tech, the “Sellers”); (3) Brill

CDXC / ChromaDex Corporation / Pioneer Step Holdings Ltd - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 15)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Lim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number: 001-37752

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or org

ChromaDex Corporation Reports Second Quarter 2024 Financial Results Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven net loss and positive Adjusted EBITDA o

ChromaDex Corporation Reports Second Quarter 2024 Financial Results Total net sales of $22.

ChromaDex Earnings Presentation Second Quarter 2024 Rob Fried Chief Executive Officer James Lee Interim Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 7, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT

ChromaDex Earnings Presentation Second Quarter 2024 Rob Fried Chief Executive Officer James Lee Interim Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 7, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 CHROMADEX CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Letter Agreement and Consulting Agreement, dated as of June 25, 2024, by and between the Company and Brianna Gerber

EXHIBIT 10.1 June 25, 2024 VIA ELECTRONIC MAIL ONLY Brianna Gerber [email protected] Dear Brianna: You have notified us that you are resigning your employment at ChromaDex Corporation (the “Company”), including officer and board roles at all of its subsidiaries, effective at the close of business on July 12, 2024 (the “Separation Date”). We wish you well in your future endeavors. You hereby con

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CHROMADEX CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number: 001-3775

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or or

ChromaDex Corporation Reports First Quarter 2024 Financial Results

ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.

ChromaDex Earnings Conference Call First Quarter 2024 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 8, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 Th

ex992-investorpresentati ChromaDex Earnings Conference Call First Quarter 2024 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 8, 2024 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Amended and Restated Incentive Compensation Recoupment Policy

Exhibit 10.60 CHROMADEX CORPORATION AMENDED AND RESTATED INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) has determined that it is in the best interests of the Company to adopt this Amended and Restated Incentive Compensation Recoupment Policy (the “A&R Policy”), which amends and restates the Company’s Incentive

Fourth Amendment to Lease, dated December 20, 2018, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.

Exhibit 10.24 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this "Fourth Amendment") is made and entered into as of December 20, 2018, by and between 10900 WILSHIRE, L.L.C., a Delaware limited liability company ("Landlord"), and CHROMADEX, INC., a California corporation ("Tenant"). RECITALS: A. Landlord and Tenant are parties to that certain Leaser dated July 6, 2017 (the "Office Lease

Subsidiaries of ChromaDex Corporation

EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2023) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlık Ürünleri Anonim Şirketia ChromaDex

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin

EXHIBIT 99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows. LOS ANGELES, CA - M

Dodd-Frank Clawback Policy

Exhibit 97.1 CHROMADEX CORPORATION Dodd-Frank Clawback Policy The Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Dodd-Frank Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined belo

ChromaDex Earnings Conference Call Fourth Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 6, 2024 2 SAFE HARBOR STATEMENT This presentation and

ChromaDex Earnings Conference Call Fourth Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 6, 2024 2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Fourth Modification to Business Financing Agreement dated November 9, 2023 by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex Inc. and ChromaDex Analytics, Inc.

EXHIBIT 10.1 FOURTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Fourth Modification to Business Financing Agreement (this “Amendment”) is entered into as of November 9, 2023, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, and CHROMADEX ANALYTICS, INC., a Nevada corporation (indiv

Fifth Modification to Business Financing Agreement dated December 8, 2023 by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex Inc. and ChromaDex Analytics, Inc.

EXHIBIT 10.2 FIFTH MODIFICATION TO BUSINESS FINANCING AGREEMENT This Fifth Modification to Business Financing Agreement (this “Amendment”) is entered into as of December 8, 2023, by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, and CHROMADEX ANALYTICS, INC., a Nevada corporation (individ

First Amendment to the Amended and Restated Supply Agreement, dated August 16, 2023, by and between the Company, Nestec Ltd. and NHSc **

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO AMENDED AND RESTATED SUPPLY AGREEMENT This First Amendment to Amended and Restated Supply Agreement (the “First Amendment”) is entered into this August 16, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o

ChromaDex Earnings Conference Call Third Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | November 8, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT

ChromaDex Earnings Conference Call Third Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | November 8, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Ninth Amendment to Manufacturing and Supply Agreement, dated as of November 2, 2023, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn.**

Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. NINTH AMENDMENT Manufacturing and Supply Agreement between W. R. Grace & Co.-Conn. and ChromaDex, Inc. This Ninth Amendment (the “Ninth Amendment") to that certain Manufacturing and Supply Ag

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Sixth Amendment to Lease, dated October 11, 2023, by and between 10900 WILSHIRE L.L.C and ChromaDex, Inc.

Exhibit 10.1 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (this "Sixth Amendment") is made and entered into as of October 11, 2023, by and between 10900 WILSHIRE, L.L.C., a Delaware limited liability company ("Landlord"), and CHROMADEX, INC., a California corporation ("Tenant"). R E C I T A L S : A.Landlord and Tenant are parties to that certain Lease, dated July 6, 2017 (the "Original L

ChromaDex Corporation Reports Third Quarter 2023 Financial Results Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows f

ChromaDex Corporation Reports Third Quarter 2023 Financial Results Total net sales of $19.

CDXC / Chromadex Corp / Champion River Ventures Ltd - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHlNGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 8)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Champion River Ventures Li

Joint Filing Agreement

EX-99.1 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have

ChromaDex Earnings Conference Call Second Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 9, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT

ex992-earningspresentati ChromaDex Earnings Conference Call Second Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 9, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 CHROMADEX CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi

ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive o

ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Commission File Number: 001-37752

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or org

$47,800,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-272828 PROSPECTUS SUPPLEMENT (To Prospectus dated July 5, 2023) $47,800,000 Common Stock We have entered into an At Market Issuance Sales Agreement (the “Sales Agreement”), dated as of June 12, 2020, with B. Riley Securities, Inc. (“B. Riley Securities”) and Raymond James & Associates, Inc. (“Raymond James” and together with B. Riley Securities

CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024

CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024 June 30, 2023 VIA EDGAR Jason Drory United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: ChromaDex Corporation Registration Statement on Form S-3 (File No. 333-272828) Dear Mr. Drory: Pursuant to Rule 461 of the Securities Act of 1933, as amended

LETTER

United States securities and exchange commission logo June 27, 2023 Robert Fried Chief Executive Officer ChromaDex Corp.

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.8 ChromaDex Corporation and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of ChromaDex Corporation Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between ChromaDex Corporation, a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing

Form of Indenture, by and between the Registrant and one or more trustees to be named.

Exhibit 4.4 CHROMADEX CORPORATION, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities Table of Contents Page Article 1 DEFINITIONS 1 Section 01. Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 01. Designation and Terms of Securities 5 Section 02. Form of Securities and Trustee’s Certificate 8 Section

As filed with the Securities and Exchange Commission on June 22, 2023

As filed with the Securities and Exchange Commission on June 22, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) ChromaDex Corporation (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0.

Filing Fee Table

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) ChromaDex Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) (2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0.

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.7 ChromaDex Corporation and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of ChromaDex Corporation Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between ChromaDex Corporation, a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under th

As filed with the United States Securities and Exchange Commission on June 22, 2023

As filed with the United States Securities and Exchange Commission on June 22, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 CHROMADEX CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

ChromaDex Corporation 2017 Equity Incentive Plan, as amended

Exhibit 10.1 ChromaDex Corporation AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders June 22, 2018 Amended by the Board of Directors: April 16, 2020 Approved by the Stockholders June 19, 2020

ChromaDex Earnings Conference Call First Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 10, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 T

ChromaDex Earnings Conference Call First Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 10, 2023 SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respec

ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission File Number: 001-3775

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 CHROMADEX CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

ARS

Test Text This page left blank.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 CHROMADEX CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi

Amended and Restated Bylaws of the Registrant

EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF CHROMADEX CORPORATION (hereinafter called the “Corporation”) ARTICLE I. OFFICES Section 1.Registered Office. The registered office of the Corporation in the State of Delaware shall be in the Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware, 19801 and the name of the registered agent of the Corporation

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EBITDA profit of $0.4 million. F

EXHIBIT 99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EBITDA profit of $0.4 million. Full year total net sales of $72.0 million with $60.1 million from Tru Niagen. LOS ANGELES, CA - March 8, 2023 - ChromaDex Corp. (NASDAQ:C

Subsidiaries of ChromaDex Corporation

EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2022) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlık Ürünleri Anonim Şirketia ChromaDex

Eighth Amendment to Manufacturing and Supply Agreement, dated as of December 14, 2022, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn.**

EXHIBIT 10.50 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EIGHTH AMENDMENT Manufacturing and Supply Agreement between W. R Grace & Co. and ChromaDex, Inc. This Eighth Amendment to the Manufacturing and Supply Agreement (the "Eighth Amendment") is m

Waiver of bonus compensation agreement dated February 13, 2023, by and between Frank L. Jaksch Jr. and ChromaDex, Inc. +

EXHIBIT 10.6 WAIVER OF 2022 BONUS COMPENSATION I, Frank L. Jaksch, Jr., hereby affirm and state that on June 3, 2022, I notified ChromaDex Corporation (the “Company”) that I intended to resign from my capacity as Executive Director and an employee of the Company, and as an officer, employee, and director of any subsidiaries of the Company. I continue to serve on the board of directors (the “Board”

ChromaDex Earnings Conference Call Fourth Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 8, 2023 2 SAFE HARBOR STATEMENT This presentation and

cdxcearningspresentation ChromaDex Earnings Conference Call Fourth Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 8, 2023 2 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 CHROMADEX CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Executive Employment Agreement, dated January 1, 2023, by and between Brianna Gerber and the Registrant

EX-10.1 2 gerberbriannaexecutiveem.htm EX-10.1 CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT for Brianna Gerber This Executive Employment Agreement (this “Agreement”) is entered into as of January 1, 2023 (the “Effective Date”), by and between Brianna Gerber (“Executive”) and ChromaDex Corporation, a Delaware corporation (the “Company”). This Agreement supersedes and replaces all prior offe

ChromaDex Named Brianna Gerber Chief Financial Officer LOS ANGELES – January 5, 2023 – ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financia

ChromaDex Named Brianna Gerber Chief Financial Officer LOS ANGELES ? January 5, 2023 ? ChromaDex Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 CHROMADEX CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission F

2,480,000 Shares Common Stock Offered by the Selling Stockholders

Filed pursuant to Rule 424(b)(3) Registration No. 333-268148 PROSPECTUS 2,480,000 Shares Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale by certain selling stockholders from time to time of up to 2,480,000 shares of our common stock, par value $0.001 per share (?Common Stock?). The selling stockholders may sell the shares of Common Stock described i

CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024

CHROMADEX CORPORATION 10900 Wilshire Blvd. Suite 600 Los Angeles, CA 90024 November 14, 2022 VIA EDGAR Lauren Hamill United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: ChromaDex Corporation Registration Statement on Form S-3 (File No. 333-268148) Dear Ms. Hamill: Pursuant to Rule 461 of the Securities Act of 1933, as

LETTER

United States securities and exchange commission logo November 9, 2022 Heather Van Blarcom Senior Vice President, Legal and Corporate Secretary ChromaDex Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ChromaDex Corporation (Exact Name of Registrant As Specified in Its Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ChromaDex Corporation (Exact Name of Registrant As Specified in Its Charter) Delaware 26-2940963 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 10900 Wilshire Blvd., Suite 600 Los Angeles, California 90024 (

Calculation of Filing Fee Tables Form S-3 ChromaDex Corporation (Exact names of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Calculation of Filing Fee Tables Form S-3 ChromaDex Corporation (Exact names of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o

ChromaDex Earnings Conference Call Third Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber SVP, Finance / Interim Chief Financial Officer Nasdaq: CDXC | November 2022 SAFE HARBOR STATEMENT This presentation and other written or oral state

cdxcearningspresentation ChromaDex Earnings Conference Call Third Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber SVP, Finance / Interim Chief Financial Officer Nasdaq: CDXC | November 2022 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.1 million, with gross margin of 59.8%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.0 million and $1.2 million, respectively, fo

ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.

Amended and Restated Supply Agreement, dated October 10, 2022, by and between the Company, Nestec Ltd. and NHSc

cdxc-amendedandrestateds 276544406 v1 1 of 42 NHSc’s and ChromaDex’s Initials CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 CHROMADEX CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

CDXC / Chromadex Corp / Societe des Produits Nestle S.A. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CHROMADEX CORPORATION (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 171077407 (CUSIP Number) Nestl? S.A. Avenue Nestl?, 55 1800 Vevey Switzerland Attention: General Counsel Facsimile: 011-41-21-924-2821 with a copy to: David A. Carpenter, E

JOINT FILING AGREEMENT

EXHIBIT I JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

3,816,794 Shares Common Stock

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-239144 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 26, 2020) 3,816,794 Shares Common Stock We are offering to an institutional investor 3,816,794 shares of our common stock at a price of $1.31 per share pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on the Nasdaq Capital Market u

Securities Purchase Agreement, dated as of October 10, 2022, by and between the Company and the Purchaser

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 10, 2022, between ChromaDex Corporation, a Delaware corporation (the ?Company?), and Soci?t? des Produits Nestl? SA, a soci?t? anonyme organized under the laws of Switzerland (the ?Purchaser?). WHEREAS, the Company and the Purchaser are parties to that certain supply agreement da

ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

Exhibit 99.1 ChromaDex and Nestl? Health Science Announce New Niagen? Commercial Supply Agreement and $5 Million Investment ? The new agreement extends non-exclusive rights to sell Niagen? in multi-ingredient dietary supplements ? The agreement includes an initial Niagen? ingredient purchase commitment of $1.975 million in 2022 ? ChromaDex will be eligible to receive commercial milestone payments,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2022 CHROMADEX CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Shareholders Agreement, effective as of September 30, 2022, between Hong Kong Taikuk (China) Group Ltd. and the Company’s named subsidiaries

Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SHAREHOLDERS AGREEMENT among HONG KONG TAIKUK (CHINA) GROUP LTD. ASIA PACIFIC SCIENTIFIC, INC. and CHROMADEX ASIA PACIFIC VENTURES LIMITED DATED: SEP

CDXC / Chromadex Corp / Champion River Ventures Ltd - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 7)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Champion River Ventures Limited Att

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed

Good-Bye! (Leaving the SEC Website) This page is temporarily unavailable.

Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed

Registration Rights Agreement, dated as of September 30, 2022, by and among the Registrant and the parties thereto

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the ?Agreement?) is made as of September 30, 2022, by and among ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the ?Company?), and each purchaser signatory hereto (each, a ?Purchaser? and collectively to the extent there is more than one Purchaser, the ?Purchasers?).

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commissio

Termination Agreement, dated as of September 30, 2022, by and between ChromaDex Corporation, Crystal Lake Developments Limited, Pioneer Idea Holdings Limited, and Hong Kong Taikuk (China) Group Ltd (incorporated herein by reference to Exhibit 10.4 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 3, 2022).

Exhibit 10.4 TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this ?Agreement?) is entered into on September 30, 2022 (the ?Effective Date?) by and among ChromaDex Corporation, a Delaware corporation (?CDXC?), Crystal Lake Developments Limited, a company incorporated under the laws of the British Virgin Islands (?Crystal Lake?), Pioneer Idea Holdings Limited, a company organized under the laws of

Securities Purchase Agreement, dated September 30, 2022, by and among the Company and the Purchasers

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 30, 2022, by and among ChromaDex Corporation, a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively to the extent there is more than one Purchaser, the ?Pur

CDXC / Chromadex Corp / Pioneer Step Holdings Ltd - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHlNGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 14)* CHROMADEX CORPORATION (Name of lssuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Limited Dvor

CT ORDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION September 7, 2022 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 ChromaDex Corporation File No.

Letter Agreement, dated August 10, 2022, by and between the Company and Kevin Farr (incorporated by reference from and filed as Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-37752) filed with the Commission on August 10, 2022)

Exhibit 10.1 August 10, 2022 VIA ELECTRONIC MAIL ONLY Kevin Farr [email protected] Dear Kevin: Please be advised that the Company is terminating your employment without Cause, as that term is defined in your Executive Employment Agreement dated October 5, 2017 (the ?EEA?). The ?Termination Date? for the purposes of this Agreement will be August 12, 2022. The separation benefits contemplated by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number: 001-37752

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or org

Consultant Agreement, dated August 10, 2022, by and between the Company and Kevin Farr

Exhibit 10.2 CONSULTANT AGREEMENT This Consultant Agreement (the ?Agreement?) is entered into this August 13, 2022 (?Effective Date?) by and between ChromaDex, Inc., having its principal offices located 10900 Wilshire Blvd., Suite 600, Los Angeles, California 90024, U.S.A. (?ChromaDex?), and Kevin M. Farr, with an address of 412 Via Almar, Palos Verdes Estates, California 90274, U.S.A. (?Consultan

EX-99.2

Exhibit 99.2

ChromaDex Corporation Reports Second Quarter 2022 Financial Results Total net sales of $16.7 million for the three months ended June 30, 2022 with $14.5 million from Tru Niagen® and gross margin of 60.0% for the quarter.

Exhibit 99.1 ChromaDex Corporation Reports Second Quarter 2022 Financial Results Total net sales of $16.7 million for the three months ended June 30, 2022 with $14.5 million from Tru Niagen® and gross margin of 60.0% for the quarter. LOS ANGELES, CA - August 10, 2022 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022. Second Quarter 2022 and Recent Hig

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi

CDXC / Chromadex Corp / Yong Rong (HK) Asset Management Ltd - 20220625 13G/A REPORT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 ChromaDex Corporation (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) June 22, 2022. (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed

Joint Filing Agreement

EX-99.1 Exhibit 99.1 Joint Filing Agreement The persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have

CDXC / Chromadex Corp / Pioneer Step Holdings Ltd - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 13)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Pioneer Step Holdings Limited Dvor

CDXC / Chromadex Corp / SHING LI KA - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* CHROMADEX CORPORATION (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) Champion River Ventures Limited Att

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File

ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China The signed agreement establishes beachhead to broadly market and distribute Tru Niagen® to Mainland China’s aging population

Exhibit 99.1 ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China The signed agreement establishes beachhead to broadly market and distribute Tru Niagen? to Mainland China?s aging population LOS ANGELES, CA - May 19, 2022 - ChromaDex Corp. (NASDAQ:CDXC) (?the Company?) a global bioscience company dedicated to healthy aging, today announced it has entered into an agree

Joint Venture Agreement, dated as of May 19, 2022, by and between ChromaDex Corporation, Crystal Lake Developments Limited, Pioneer Idea Holdings Limited and Hong Kong Taikuk (China) Group Ltd (incorporated herein by reference to Exhibit 1 0.1 of the Issuer’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 19, 2022).

Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. JOINT VENTURE AGREEMENT THIS JOINT VENTURE AGREEMENT (this ?Agreement?) is made as of May 19, 2022 (the ?Effective Date?) between Crystal Lake Develo

First Amendment to the Amended and Restated Exclusive License Agreement, effective as of December 29, 2020, between Dartmouth College and ChromaDex, Inc.

Exhibit 10.2 AMENDMENT TO THE CHROMADEX, INC. - DARTMOUTH RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Amendment (this ?Amendment?), dated as of this 29th day of December, 2020 with effect from and after March 13, 2017 (the ?Amendment Effective Date?), to the ChromaDex, Inc. - Dartmouth Restated and Amended Exclusive License Agreement, dated September 2019 (?License Agreement?), is made b

Transition and Separation Agreement, effective July 8, 2021, between Lisa Harrington and ChromaDex, Inc. ❖ (2)

Exhibit 10.7 ChromaDex Corporation July 8, 2021 Lisa Hatton Harrington Newport Coast, CA 92657 Re: Transition and Separation Agreement Dear Lisa: This letter sets forth the substance of the transition and separation agreement (the ?Agreement?) that ChromaDex Corporation (the ?Company?) is offering to you to aid in your employment transition. 1.Separation. Your last day of work with the Company and

ChromaDex Earnings Conference Call First Quarter 2022 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 2022 SAFE HARBOR STATEMENT This presentation and other written

ChromaDex Earnings Conference Call First Quarter 2022 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 2022 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934.

Joint Ownership Management Agreement, effective October 9, 2015, between Queen’s University of Belfast and ChromaDex, Inc.

Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. JOINT OWNERSHIP MANAGEMENT AGREEMENT This Joint Ownership Management Agreement (?Agreement?) is made effective the 09 October 2015 (?Effective Date?) by and between (1) THE QUEEN?S

Side letter agreement to the Amended and Restated Exclusive License Agreement, effective as of March 13, 2019, between Dartmouth College and ChromaDex, Inc.

Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. September 3, 2019 Ms. Nila Bhakuni Director Technology Transfer Office Dartmouth College 11 Rope Ferry Road, HB 6210 Hanover, New Hampshire 03755 Chromadex - Dartmouth Side Letter Agreement: De

Restated and Amended Exclusive License Agreement, effective as of March 13, 2017, between Dartmouth College and ChromaDex, Inc.

Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CHROMADEX, INC. - DARTMOUTH RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Agreement, effective the 13th day of March 2017 between TRUSTEES OF DARTMOUTH COLLEGE, a non-profi

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission File

First Amendment to the Joint Ownership Management Agreement, effective March 9, 2022, between Queen’s University of Belfast and ChromaDex, Inc.

Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT TO / JOINT OWNERSHIP MANAGEMENT AGREEMENT THIS AMENDMENT is entered into this 10th day of March 2022 (the ?Effective Date of the Amendment?), by and between ChromaDex, In

ChromaDex Corporation Reports First Quarter 2022 Financial Results Total net sales of $17.3 million for the three months ended March 31, 2022, up 18% from the prior year, with $14.9 million from Tru Niagen® and gross margin of 61.0% for the quarter.

ChromaDex Corporation Reports First Quarter 2022 Financial Results Total net sales of $17.

Second Amendment to the Amended and Restated Exclusive License Agreement, effective as of January 1, 2022, between Dartmouth College and ChromaDex, Inc.

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO THE CHROMADEX, INC. - DARTMOUTH RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Amendment (this ?Amendment?), effective as of this 1st day of January, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Commission File Number: 001-3775

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

Investor Presentation Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer Nasdaq: CDXC | March 2022 ChromaDex Investment Highlights • Leader in the rapidly growing NAD+ market • Proven and proprietary NAD+ boosting supplement support

Investor Presentation Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer Nasdaq: CDXC | March 2022 ChromaDex Investment Highlights ? Leader in the rapidly growing NAD+ market ? Proven and proprietary NAD+ boosting supplement supported by 20 clinical trials ? Strong revenue growth (34% CAGR(1)) driven by e-commerce and strong gross margins (61.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fi

Subsidiaries of ChromaDex

EX-21.1 6 subsidiariesofchromadexcor.htm EX-21.1 SUBSIDIARIES OF THE REGISTRANT (As of December 31, 2021) Entity Name President Company / Owner Jurisdiction of Formation ChromaDex, Inc. ChromaDex Corporation California ChromaDex International, Inc. ChromaDex Corporation Cayman Islands ChromaDex Analytics, Inc. ChromaDex, Inc. Nevada ChromaDex Europa B.V. ChromaDex, Inc. Netherlands Chromadex Sağlı

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission file number 001-37752 CHROMADEX CORPORATION (

Amended and Restated Bylaws of the Registrant

EX-3.3 2 chromadex-amendedandrestat.htm EX-3.3 AMENDED AND RESTATD BYLAWS OF CHROMADEX CORPORATION (hereinafter called the “Corporation”) ARTICLE I. OFFICES Section 1.Registered Office. The registered office of the Corporation in the State of Delaware shall be in the Corporation Trust Center, 1209 Orange Street, in the ‘City of Wilmington, County of New Castle, Delaware, 19801 and the name of the

Second Modification to Business Financing Agreement dated November 10, 2021, by and between ChromaDex Corporation and Western Alliance Bank

SECOND MODIFICATION TO BUSINESS FINANCING AGREEMENT This Second Modification to Business Financing Agreement (this ?Amendment?) is entered into as of November 10, 2021, by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Lender?), CHROMADEX CORPORATION, a Delaware corporation, and CHROMADEX, INC.

Lease, dated November 24, 2021, by and between Flight Phase I Owner, LLC and ChromaDex, Inc.

EX-10.59 5 leasedatednovember242021by.htm EX-10.59 OFFICE LEASE AGREEMENT CALIFORNIA FLIGHT AT TUSTIN LEGACY TUSTIN, CA THIS OFFICE LEASE AGREEMENT (the "Lease") is made and entered into as of the 24th day of November, 2021, by and between FLIGHT PHASE I OWNER, LLC, a Delaware limited liability company ("Landlord") and CHROMADEX CORPORATION, a Delaware corporation ("Tenant"). Pursuant to the terms

Supply Agreement, dated December 19, 2018, by and between ChromaDex, Inc. and Nestec Ltd. *

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission Fil

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million

EX-99.1 2 exhibit991-pressreleasexq4.htm EX-99.1 ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended December 31, 2021, up 15% from the prior year quarter. LOS ANGELES, CA - M

1 ChromaDex Earnings Conference Call Fourth Quarter 2021 Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 9, 2022 2SAFE HARBOR STATEMENT This presentation and ot

1 ChromaDex Earnings Conference Call Fourth Quarter 2021 Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 9, 2022 2SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain ?forward- looking statements? within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934.

CDXC / Chromadex Corp / Li Ka Shing (Global) Foundation - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* ChromaDex Corporation (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

Joint Filing Agreement

EX-99.1 2 d187133dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The unders

CDXC / Chromadex Corp / Yong Rong (HK) Asset Management Ltd - 13G ANNUAL REPORT Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 ChromaDex Corporation (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) December 31, 2021. (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Third Modification to Business Financing Agreement dated December 11, 2021 by and among Western Alliance Bank, ChromaDex Corporation, ChromaDex, Inc. and ChromaDex Analytics, Inc.

THIRD MODIFICATION TO BUSINESS FINANCING AGREEMENT This Third Modification to Business Financing Agreement (this ?Amendment?) is entered into as of December 1, 2021, by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Lender?), CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 CHROMADEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-37752 26-2940963 (State or other jurisdiction of incorporation) (Commission

1 ChromaDex Earnings Conference Call Third Quarter 2021 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Fadi Karam Chief Marketing Officer Nasdaq: CDXC | November 3, 2021 2SAFE HARBOR

EX-99.2 3 cdxcearningspresentation.htm EX-99.2 1 ChromaDex Earnings Conference Call Third Quarter 2021 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Fadi Karam Chief Marketing Officer Nasdaq: CDXC | November 3, 2021 2SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representati

Exclusive License Agreement, dated September 8, 2011, by and between ChromaDex, Inc. and The Regents of the University of California **

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [?***?], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CHROMADEX CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and CHROMADEX INC.

ChromaDex Corporation Reports Third Quarter 2021 Financial Results Total company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen® net sales of $14.8 million, up 24% from the prior year quarter and gross margi

ChromaDex Corporation Reports Third Quarter 2021 Financial Results Total company net sales of $17.

Seventh Amendment to Manufacturing and Supply Agreement, dated as of August 2, 2021, by and between ChromaDex Inc. and W.R. Grace & Co.-Conn. ❖ **

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [?***?], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT CHROMADEX CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL SEVENTH AMENDMENT Manufacturing and Supply Agreement between W.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation o